ABSTRACT Background: Non-metastatic castration resistant prostate cancer (M0 CRPC) has seen important developments in drugs and diagnostic tools in the last two years. New hormonal agents have demonstrated improvement in metastasis free survival in M0 CRPC patients and have been approved by regulatory agencies in Brazil. Additionally, newer and more sensitive imaging tools are able to detect metastasis earlier than before, which will impact the percentage of patients staged as M0 CRPC. Based on the available international guidelines, a group of Brazilian urology and medical oncology experts developed and completed a survey on the diagnosis and treatment of M0 CRPC in Brazil. These results are reviewed and summarized and associated recommendations are provided. Objective: To present survey results on management of M0 CRPC in Brazil. Design, setting, and participants: A panel of six Brazilian prostate cancer experts determined 64 questions concerning the main areas of interest: 1) staging tools, 2) treatments, 3) side effects of systemic treatment/s, and 4) osteoclast-targeted therapy. A larger panel of 28 Brazilian prostate cancer experts answered these questions in order to create country-specific recommendations discussed in this manuscript. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on the predefined questions. These answers are the panelists' opinions, not a literature review or meta-analysis. Therapies not yet approved in Brazil were excluded from answer options. Each question had five to seven relevant answers including two non-answers. Results were tabulated in real time. Conclusions: The results and recommendations presented can be used by Brazilian physicians to support the management of M0 CRPC patients. Individual clinical decision making should be supported by available data, however, for Brazil, guidelines for diagnosis and management of M0 CRPC patients have not been developed. This document will serve as a point of reference when confronting this disease stage.

OBJETIVO: investigar a micronucleação (MN) em células esfoliadas do colo uterino de mulheres HIV+ observando as condições de imunidade aferidas pelos níveis de linfócitos CD4+ e da carga viral para o HIV (CV). MÉTODOS: foram obtidas coletas citológicas da junção escamocolunar de 23 pacientes HIV+ de Ambulatório de DST/AIDS. O grupo controle foi composto por mulheres assintomáticas do Ambulatório de Prevenção de Câncer Ginecológico do mesmo serviço. O material foi submetido a processamento citológico para leitura em microscopia de luz, com objetiva de imersão em 2.000 células por paciente. Para avaliação da condição imunitária das pacientes HIV+ investigamos os níveis de linfócitos CD4+ e CV. A análise estatística dos resultados se fez com os testes do Χ2 e Kolmogorov-Smirnov. RESULTADOS: vinte e três pacientes compuseram o grupo de mulheres HIV+ e 19 formaram o grupo controle. Em todas as pacientes HIV+ e em 84,2% do grupo controle detectamos MN. Dezessete pacientes HIV+ (73,9%) tiveram mais de 7 MN. No grupo controle tivemos apenas 1 caso (5,2%) com mais de 7 MN. Houve tendência na associação de maiores quantidades de MN em mulheres com baixos níveis de linfócitos CD4+ e maiores níveis de CV, sem caracterizar correlação estatística. CONCLUSÕES: pacientes HIV+ em fase de AIDS têm maior ocorrência de MN que o grupo controle e, também, a frequência com que são detectados MN parece estar associada a piores condições clínicas da imunossupressão.

PURPOSE: to investigate the micronucleation (MN) of exfoliated cells from the uterine cervix of HIV+ women according to immunocompetence status. We investigated the clinical conditions of immunocompetence by analyzing the levels of CD4+ lymphocytes and viral count for HIV (VC). METHODS: biological material was collected from 23 HIV+ patients whose cervical oncologic cytology results were negative. They were patients from the STD/AIDS-FCMS-PUCSP who underwent a cytobrush collection in the squamous columnar junction. Similar material was obtained from 19 healthy control women. The material, about 2000 cells per patient, was processed for cytology using light microscopy and an immersion objective. To analyze the immunological status of HIV+ patients we used CD4+ count and VC. Statistical analysis was performed using the Χ2 and Kolmorogov-Smirnov tests. RESULTS: twenty-three pacients composed the group of HIV+ women and 19 composed the control group. We found micronuclei (MN) in all HIV+ patients and in 84.2% of the control group. In 17 73.9% of the HIV+ patients and in 5.2% of the control group we found more than 7 MN cells. MN tended to occur more among women with poorer immunological status in the HIV+ group. CONCLUSIONS: HIV+ patients in the AIDS phase have a higher prevalence of micronucleated cells, as opposed to a control group. Also, the frequency of MN was associated with worse conditions of immunosuppression.